5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Patients come from populations and populations contain patients. A two-stage scientific and ethics review: The next adaptation for single institutional review boards.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          For nearly 50 years, institutional review boards (IRB) and independent ethics committees have featured local oversight as a core function of research ethics reviews. However growing complexity in Alzheimer's clinical research suggests current approaches to research volunteer safety is hampering development of new therapeutics. As a partial response to this challenge, the NIH has mandated that all NIH-funded multi-site studies will use a single Institutional Review Board. The perspective describes a joint program to provide a single IRB of record (sIRB) for phases of multi-site studies.

          Related collections

          Author and article information

          Journal
          Alzheimers Dement
          Alzheimer's & dementia : the journal of the Alzheimer's Association
          Elsevier BV
          1552-5279
          1552-5260
          Aug 2017
          : 13
          : 8
          Affiliations
          [1 ] Mayo Clinic College of Medicine, Rochester, MN, USA.
          [2 ] Schulman IRB, Research Triangle Park, NC, USA.
          [3 ] Schulman IRB, Cincinnati, OH, USA.
          [4 ] National Biomedical Research Ethics Council, Las Vegas, NV, USA. Electronic address: ara@pad2020.org.
          Article
          S1552-5260(17)30231-5
          10.1016/j.jalz.2017.06.001
          28709585
          aca90d55-a4a0-46b2-bf58-351579914ddf
          History

          Alzheimer's,Clinical trial,Dementia,EMEA,Ethics,FDA,IRB,Intervention,Prevention,Therapeutic,Treatment

          Comments

          Comment on this article